Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia
Imatinib dose reduction after achieving MMR does not adversely affect response deepening or MMR maintenance in chronic-phase CML but compromises MR<sup>4</sup> maintenance. The results of ddPCR may identify people who benefit from imatinib dose reduction.
Authors
- Yijing Zhao (ORCID: https://orcid.org/0000-0002-1996-7831)
- Xiaoshuai Zhang (ORCID: https://orcid.org/0000-0001-5405-0802)
- Ya-Zhen Qin
- Yong Guo (ORCID: https://orcid.org/0000-0003-3175-3008)
- Zongru Li (ORCID: https://orcid.org/0000-0002-9807-6067)
- Robert Peter Gale (ORCID: https://orcid.org/0000-0002-9156-1676)
- Qian Jiang (ORCID: https://orcid.org/0000-0001-7131-0522)
- Linping Lu
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Imperial College London (GB)
- Tsinghua University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1002/cncr.35565
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- National Natural Science Foundation of China
- Peking University
- Peking University People's Hospital
- Beijing Nova Program
- Fundamental Research Funds for the Central Universities